A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

NCT05429593 · Completed

Last updated 2026-05-28

This study tests how a single tablet combining semaglutide and dapagliflozin is processed in the bodies of healthy volunteers.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 152 people

Who can join Ages 18–64 · all sexes Healthy volunteers accepted.

Timeline Started 2022-06 · est. completion 2023-04

Where 2 sites · Germany

What this study is testing ClinicalTrials.gov NCT05429593 ↗

Description as written by the study sponsor.

This study will test how the active substances semaglutide and dapagliflozin act in the body (in terms of their levels in the blood), when they are taken in the form of a combination preparation (a tablet with a fixed dose combination) compared to when oral semaglutide and dapagliflozin are given alone.The study will consist of 2 parts. Part 1 will compare semaglutide to the fixed dose combination tablet (semaglutide/dapagliflozin) and part 2 will compare dapagliflozin to the fixed dose combination tablet (semaglutide/dapagliflozin). Participants will take part in either part 1 or part 2.

Treatments tested

Semaglutide Drug

Tablet given orally
Dapagliflozin Drug

Tablet given orally
Semaglutide/dapagliflozin Drug

Tablet given orally

Main thing measured	AUC0-24h,sema,ss: area under the semaglutide plasma concentration-time curve during a dosing interval (0 to 24 hours) at steady state
Sponsor	Novo Nordisk A/S
Conditions studied	Healthy Volunteers
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05429593 ↗